2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1611 Less is more! optimizing frequency of bone marrow evaluations in pediatric patients with acute myeloid leukemia: A retrospective study

Keishla Gonzalez, MD, Braden Soren Olsen, MD2, Kelly Maloney, MD3, Maureen O'Brien, MD4, Amanda C Winters, MD,PhD5
1 University of Colorado, Aurora, Colorado, United States
2 University of Colorado, Aurora, Colorado, United States
3 University of Colorado, Aurora, Colorado, United States
4 University of Colorado, Aurora, Colorado, United States
5 University of Colorado, Aurora, Colorado, United States

Pediatric acute myeloid leukemia (AML) is the second most common hematologic malignancy in children and carries a 30% overall risk of relapse. Traditionally, research protocols require a bone marrow examination at the end of each therapy cycle. This results in more sedated procedures, increasing the risk of procedural trauma and psychological distress, as well as the risk of cumulative, dose-dependent neurocognitive impairment associated with propofol exposure. While it is widely accepted that bone marrow evaluations after the end of therapy (EOT) do not improve capture of relapse or survival outcomes, no studies have evaluated whether on-therapy or EOT marrows in AML patients provide clinical benefit after minimal residual disease (MRD)-negative remission is achieved. The goal of this study was to determine the frequency of subclinical relapse detected on serial bone marrow evaluations during frontline AML therapy.

We conducted a retrospective cohort study of pediatric patients with newly diagnosed AML treated at Children's Hospital Colorado from 1995 to 2022. Patients aged 0 to 26 years who underwent diagnostic evaluation and received oncologic therapy for de novo AML at our institution were included. Exclusion criteria were as follows: (1) Patients who did not meet criteria for AML diagnosis; (2) Patients who did not survive the diagnostic or treatment period; (3) Patients with clinical reasons for closer monitoring (proceeding to HSCT after first complete remission (CR), induction failure, persistently positive MRD, therapy-related AML, history of TAM, MDS, or Monosomy 7) and (4) Patients who received primary oncologic treatment at another institution. We reviewed bone marrow aspiration and biopsy results, including morphology, immunophenotyping, cytogenetics, somatic mutations, chromosomal alterations, MRD status (if available), and CNS status. For those cases with subsequent relapse, we identified whether relapse occurred while receiving therapy or off therapy. We then determined whether the relapse was identified during routine surveillance bone marrow examination or triggered by symptoms or abnormal blood counts.

A total of 315 charts were reviewed. Of these, 194 patients were excluded due to one of the factors listed above, leaving 121 AML patients for evaluation. Median age at diagnosis was 12 years; 37.2% were low-risk, 29.8% intermediate-risk, 15.7% high-risk, 16.5% APML and 0.8% had insufficient data. MRD was available for 34 patients (28%). We identified 10 patients with AML who relapsed during therapy. One patient with acute myelomonocytic leukemia had a bone marrow relapse after Induction II, identified on routine bone marrow evaluation. A patient with acute myelomonocytic leukemia also relapsed on therapy after peripheral blasts were identified on the smear during Intensification I.  One patient with acute megakaryoblastic leukemia was found to have cytogenetic relapse at their EOT bone marrow evaluation. One patient with acute myelomonocytic leukemia and leukemia cutis achieved CR at the end of induction but later had leukemia cutis relapse prior to Induction II. Six patients were diagnosed with CNS relapse after developing CNS symptoms or during routine CSF analysis. Of our 10 patients who relapsed during therapy, 3 were identified based on clinical suspicion, 5 were identified while receiving intrathecal therapy or on CSF evaluation at the end of therapy, and 2 were found through surveillance marrow evaluation (1 on therapy, 1 EOT). 

Our findings suggest that relapse of AML during therapy is rare in the pediatric population. In our AML cohort, relapse was found by on-therapy marrow surveillance in <2% of patients. To our knowledge, most pediatric institutions follow the same guidelines, in which a bone marrow examination is part of routine surveillance at the end of each cycle. This study has three main limitations: a small cohort size, the retrospective nature with limited chart data, and a wide range of clinical data available since some patients were evaluated in the MRD area and others prior to MRD being available. Thus, future steps include expansion to a larger cohort size through the addition of a prospective study of patients receiving AML therapy, comparing standard regimens with reduced procedures. Decreasing the number of bone marrow samples and, subsequently, the number of sedations and procedures may be possible in pediatric AML without affecting clinical outcomes or prognosis.



Keishla Gonzalez, MD: No relevant conflicts of interest to declare.